FEATURE
Where does your health stand today?
I was diagnosed in 2005, more than a decade ago, but
have had two relapses since then.
Five years after I was initially diagnosed, I had my first
relapse. I was treated again with aggressive chemotherapy
and went on to have a bone marrow transplant, with my
younger brother as the donor. Despite that aggressive treatment approach, I did extremely well and recovered uneventfully with no significant complications. I completed
my clinical portion of my fellowship and joined the lab of
Timothy J. Ley, MD, to start my post-doctoral research.
Three years after that, I relapsed again. I tried aggressive chemotherapy again, but it didn’t put me into
remission. But, because I had the good fortune of being
at Washington University and working on the genomics
of leukemia, Dr. Ley and others decided to sequence my
genome. Based on those sequencing results, they were
able to identify a drug, sunitinib, which wouldn’t have
ordinarily been used to treat my disease, but which put
me into remission. I was able to get a second stem cell
transplant from an unrelated donor in October 2011 and
have remained in remission since.
CMYK
EN
I haven’t been able to continue to take sunitinib due to
the side effects, and only took it for a very short time after
the transplant. The biggest issue is that my transplant has
been complicated by moderate to severe graft-versus-host
disease.
What did sunitinib target?
When Dr. Ley and the genomic analysts looked at the
whole-genome sequencing data, there were multiple
alterations that were recognized as being relevant
to leukemogenesis – none of which were targetable.
DE
When multiple myeloma relapses
AV NEW
OR †
ST
U
RESPOND
with the superior power of the KYPROLIS doublet (Kd)
1
*
plus dexamethasone (Kd) provided double the median PFS vs bortezomib
plus dexamethasone ( Vd) in patients with relapsed multiple myeloma.1
* KYPROLIS
NEW HEAD-TO-HEAD DATA VS BORTEZOMIB DOUBLET (Vd) SHOWED
Median PFS1
2x
INCREASED
Complete response or better (≥ CR)1
• 18.7 months for Kd vs 9.4 months for Vd,
one-sided P < 0.00011
• 13% for Kd vs 6% for Vd1
See more results at Kyprolis-HCP.com
ENDEAVOR†: A phase 3, randomized, open-label, multicenter superiority study compared KYPROLIS plus dexamethasone (Kd) to bortezomib plus dexamethasone (Vd) in subjects
with relapsed or refractory multiple myeloma. 929 patients were randomized in a 1:1 ratio to receive Kd (n = 464) for 28-day cycles or Vd (n = 465) for 21-day cycles until disease
progression or unacceptable toxicity occurred. Patient stratification included prior proteasome inhibitor therapy (either bortezomib or carfilzomib, or no prior therapy), prior lines
of therapy (1 versus 2 or 3), current International Staging System stage (1 versus 2 or 3), and planned route of bortezomib administration (intravenous versus subcutaneous).
The primary endpoint was progression-free survival (PFS); select secondary endpoints included overall survival, overall response rate, duration of response, safety.1,2
†
ENDEAVOR = RandomizEd, OpeN label, Phase 3 Study of Carfilzomib Plus DExamethAsone
Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma.
References: 1. KYPROLIS ENDEAVOR [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.,
an Amgen Inc. subsidiary; 2016. 2. Dimopoulos MA, et al. Lancet Oncol. 2015. Published online December 5, 2015.
Accessed December 9, 2015. http://dx.doi.org/10.1016/S1470-2045(15)00464-7.
DY